PMV Pharmaceuticals, Inc.PMVPEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
PMV Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies targeting mutations in the p53 tumor suppressor gene, one of the most frequently altered genes in human cancers. Its lead product candidates address unmet medical needs for patients with hard-to-treat solid and hematologic malignancies, serving global oncology patient segments.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| OrbiMed Advisors LLC | 13.50% | 6.6M | — | 2023-08-23 |
| ArrowMark Colorado Holdings, LLC | 7.08% | 3.6M | ▲ +1.77pp | 2024-11-14 |
| BML Investment Partners, L.P. | 6.30% | 3.3M | — | 2024-12-12 |
| The Vanguard Group | 4.70% | 2.4M | — | 2024-02-13 |
| BlackRock, Inc. | 2.30% | 1.2M | ▼ -4.00pp | 2024-07-08 |
| Citadel Advisors LLC | 2.20% | 51.2M | ▼ -1.10pp | 2024-02-14 |
| STATE STREET CORPORATION | 1.41% | 69.4K | flat | 2024-01-23 |
| Boxer Capital, LLC | 0.00% | 69.4K | — | 2024-02-14 |
| Avoro Capital Advisors LLC | 0.00% | 69.4K | — | 2024-02-14 |
| RTW Investments, LP | 0.00% | 69.4K | — | 2024-02-14 |
| NOS. OF ABOVE PERSONS | 0.00% | 15.6K | ▼ -7.10pp | 2024-04-09 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
No transactions match these filters.